Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, ...

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announces the repayment of its $600,000 promissory note (the “Note”) to Nirland Limited (“Nirland”) and provided an ...

This transition to Phase II marks a positive step forward in Conduit’s strategy to explore the integration advanced artificial intelligence (AI) and cybernetics into its drug development processes.

Conduit is planning how to effectively integrate an advanced platform-driven approach powered by artificial intelligence and cybernetics ... ensuring a future defined by faster, more cost ...

This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio. NAPLES, Fla. and CAMBRIDGE ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

A Hong Kong biotech start-up is working with a number of university partners to conduct global clinical trials that could lead to a better way of delivering drugs for prevalent eye diseases.